C4 Therapeutics Inc. (CCCC)
NASDAQ · Healthcare
C4 Therapeutics Inc. EBITDA 2021–2025
C4 Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2021 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- C4 Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -27.4 M, a 4.62% decrease year-over-year.
- C4 Therapeutics Inc. annual ebitda for 2025 was -113.3 M, a 3.85% decrease from 2024.
- C4 Therapeutics Inc. annual ebitda for 2024 was -117.8 M, a 14.11% decrease from 2023.
- C4 Therapeutics Inc. annual ebitda for 2023 was -137.2 M, a 7.27% increase from 2022.
- C4 Therapeutics Inc. annual ebitda for 2022 was -127.9 M.
EBITDA
QUARTERLY · $B
C4 Therapeutics Inc. EBITDA — FAQ
C4 Therapeutics Inc. (CCCC) ebitda over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CCCC's ebitda history?
The chart and table above show C4 Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.